Safety Findings in Patients With AQP4+NMOSD Who Received Eculizumab or Ravulizumab in the PREVENT and CHAMPION-NMOSD Studies and Had Received Rituximab Within 1 Year Prior to Enrolment
MULTIPLE SCLEROSIS JOURNAL（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要